Smokers and those with chronic obstructive pulmonary disease (COPD) might be at increased risk for severe illness with COVID-19, reports a new study.
People who smoke or have a chronic obstructive pulmonary disease (COPD) may be at higher risk for severe complications and death from COVID-19 infection, reports a new study. The findings of the study are published in the journal PLOS ONE.// Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published on May 11, 2020, in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues. COPD is a common, persistent dysfunction of the lung associated with a limitation in airflow. An estimated 251 million people worldwide are affected by COPD. Given the effects of the SARS-CoV-2 coronavirus on respiratory function, the authors of the present study sought to understand the prevalence and the effects of COPD in COVID-19 patients.
‘COPD is a common, persistent dysfunction of the lung linked to a limitation in airflow.
’
Read More..
In the new study, researchers systematically searched databases of scientific literature to find existing publications on the epidemiological, clinical characteristics, and features of COVID-19 and the prevalence of COPD in COVID-19 patients. 123 potentially relevant papers were narrowed to 15 that met all quality and inclusion guidelines. The included studies had a total of 2473 confirmed COVID-19 patients. 58 (2.3%) of those patients also had COPD, while 221 (9%) were smokers. Read More..
Critically ill COVID-19 patients with COPD had a 63% risk of severe disease and a 60% risk of mortality while critically ill patients without COPD had only a 33.4% risk of severe disease (RR 1.88, 95% CI 1.4-2.4) and 55% risk of mortality (RR 1.1, 95% CI 0.6-1.8). In addition, current smokers were 1.45 times more likely to have severe complications compared to former and never smokers (95% CI 1.03-2.04). The study was not able to examine whether there was an association between the frequency of COPD exacerbations, or the severity of COPD, with COVID-19 outcomes or complications. The results are limited by the fact that few studies were available to review, as well as the diverse locations, settings, and designs of the included studies.
The authors add: "Despite the low prevalence of COPD and smoking in COVID-19 cases, COPD and current smokers were associated with greater COVID-19 severity and mortality."
Source-Eurekalert